The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The role of von Willebrand factor in SCD: predicting complications
Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, speaks on the role of von Willebrand factor (VOF) and its influence on vascular injury in sickle cell disease (SCD). VOF may be a marker of endothelial stress, and VOF levels could be used to predict which patients are at risk of multiple organ failure. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Advisory board: Agios, Novartis, BEAM Therapeutics, Forma Therapeutics, GBT/Pfizer
Research Funding: Novartis, Forma Therapeutics, GBT/Pfizer
Speakers Bureau: GBT/Pfizer
